Shots:

• The P-III ADAURA study involves assessing of Tagrisso (80mg- qd- PO) vs PBO for the adjuvant treatment of 682 patients with stage IB- II- IIIA EGFRm NSCLC following complete tumor resection and adjuvant CT as indicated for 3yrs. or until disease recurrence
• Results: 82% reduction in the risk of CNS recurrence or death; patients having recurrence events or deaths (11% vs 46%); patients having metastatic recurrence (38% vs 61%). In a posthoc analysis- disease recurrence in the brain @18mos. 83% reduction in risk of disease recurrence or death- presented at ESMO 2020
• Tagrisso is an irreversible EGFR-TKI with clinical activity against CNS metastases and has received BT designation in Jul’2020 for the adjuvant treatment of patients with early-stage EGFRm NSCLC after complete tumor resection with curative intent

­ Ref: AstraZeneca | Image: The Scientist Magazine